New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
08:47 EDTSRNESorrento Therapeutics and Morphotek sign drug development agreement
Sorrento Therapeutics subsidiary Concortis Biosystems announced a collaboration to generate novel antibody drug conjugates based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive research fees, up-front payment, milestone payments and royalties on future net sales. Sorrento has the potential to receive up to $50M upon successful attainment of key milestones.
News For SRNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:59 EDTSRNESorrento Therapeutics price target raised to $26 from $17 at Brean Capital
Brean Capital raised its price target on Sorrento Therapeutics (SRNE) to $26 from $17 as they believe the successful Nantkwest (NK) IPO has validated the company and its strategy. The firm noted Sorrento is an equal partner in the ownership of Nantkwest and thus feels it deserves a similar valuation, which is not priced in. Brean Capital reiterated its Buy rating on Sorrento shares.
July 23, 2015
10:05 EDTSRNEHigh option volume stocks
Subscribe for More Information
July 17, 2015
18:01 EDTSRNESorrento Therapeutics Chief Commercial Officer George Uy to leave company
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use